Early appearance of serum  -fetoprotein as a function of dosage of various hepatocarcinogens.
D000081:Acetamides / Q000008:administration & dosage; D000284:Administration, Oral; D000348:Aflatoxins / Q000008:administration & dosage; D000510:Alpha-Globulins / Q000032:analysis; D000818:Animals; D000961:Antilymphocyte Serum / Q000008:administration & dosage; D002251:Carbon Tetrachloride / Q000008:administration & dosage; D002273:Carcinogens / Q000008:administration & dosage*; D005326:Fetal Proteins / Q000032:analysis*; D005449:Fluorenes / Q000008:administration & dosage; D005779:Immunodiffusion; D007165:Immunosuppression Therapy; D007274:Injections, Intraperitoneal; D008113:Liver Neoplasms / Q000139:chemically induced* / Q000276:immunology / Q000473:pathology; D008297:Male; D009374:Neoplasms, Experimental; D009602:Nitrosamines / Q000008:administration & dosage; D051381:Rats; D013997:Time Factors; D004124:p-Dimethylaminoazobenzene / Q000008:administration & dosage
D000081:Acetamides; D000348:Aflatoxins; D000510:Alpha-Globulins; D000961:Antilymphocyte Serum; D002273:Carcinogens; D005326:Fetal Proteins; D005449:Fluorenes; D009602:Nitrosamines; D004124:p-Dimethylaminoazobenzene; D002251:Carbon Tetrachloride